<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="52717">Bortezomib</z:chebi> (<z:chebi fb="0" ids="52717">Velcade</z:chebi>) is used widely for the treatment of various human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>; however, its mechanisms of action are not fully understood, particularly in <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="52717">Bortezomib</z:chebi> is a selective and reversible inhibitor of the proteasome </plain></SENT>
<SENT sid="2" pm="."><plain>Paradoxically, we find that <z:chebi fb="0" ids="52717">bortezomib</z:chebi> induces proteasome-independent degradation of the TRAF6 protein, but not <z:chebi fb="2" ids="33699">mRNA</z:chebi>, in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) cell lines and primary cells </plain></SENT>
<SENT sid="3" pm="."><plain>The reduction in TRAF6 protein coincides with <z:chebi fb="0" ids="52717">bortezomib</z:chebi>-induced autophagy, and subsequently with <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cells </plain></SENT>
<SENT sid="4" pm="."><plain>RNAi-mediated knockdown of TRAF6 sensitized <z:chebi fb="0" ids="52717">bortezomib</z:chebi>-sensitive and -resistant cell lines, underscoring the importance of TRAF6 in <z:chebi fb="0" ids="52717">bortezomib</z:chebi>-induced cytotoxicity </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="52717">Bortezomib</z:chebi>-resistant cells expressing an shRNA targeting TRAF6 were resensitized to the cytotoxic effects of <z:chebi fb="0" ids="52717">bortezomib</z:chebi> due to down-regulation of the proteasomal subunit Î±-1 (PSMA1) </plain></SENT>
<SENT sid="6" pm="."><plain>To determine the molecular consequences of loss of TRAF6 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cells, in the present study, we applied gene-expression profiling and identified an <z:mpath ids='MPATH_3'>apoptosis</z:mpath> gene signature </plain></SENT>
<SENT sid="7" pm="."><plain>Knockdown of TRAF6 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> cell lines or patient samples resulted in rapid <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and impaired malignant hematopoietic stem/progenitor function </plain></SENT>
<SENT sid="8" pm="."><plain>In summary, we describe herein novel mechanisms by which TRAF6 is regulated through <z:chebi fb="0" ids="52717">bortezomib</z:chebi>/autophagy-mediated degradation and by which it alters <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> sensitivity to <z:chebi fb="0" ids="52717">bortezomib</z:chebi> by controlling PSMA1 expression </plain></SENT>
</text></document>